These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31508822)

  • 1. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
    Kirke DN; Kaye R; Blitzer A
    Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
    Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
    Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
    Dharia I; Bielamowicz S
    Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
    Lee SJ; Kang MS; Choi HS; Lim JY
    Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
    Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
    JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia.
    Mor N; Tang C; Blitzer A
    Otolaryngol Head Neck Surg; 2016 Sep; 155(3):458-61. PubMed ID: 27143711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
    Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
    Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
    Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
    JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
    French G; Bosch JD; Randall DR
    J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
    Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
    Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
    Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
    J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and adverse effects of unilateral or bilateral botulinum toxin injections for adductor spasmodic dysphonia: a systematic review and meta-analysis.
    Liu Y; Chen F; Liang F; Wang C; Chen D; Zhou J; Zhang L; Xiao X; He R; Tang L; Tian L; Zhou L
    Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1357-1369. PubMed ID: 38095707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
    Lerner MZ; Lerner BA; Patel AA; Blitzer A
    Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
    Namin AW; Christopher KM; Eisenbeis JF
    J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.